Cytek Biosciences, Inc. CTKB
NASDAQ · United States · Health Technology
$5.77-0.04 (-0.77%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Brown Capital Management, an investment management company, released its second-quarter 2026 investor letter for “The Brown Capital Management Small Company Fund.” The letter can be downloaded here. For the quarter ended June 30, 2026, market volatility reflected uncertainty around AI spending and Middle East tensions. The Magnificent Seven fell more than 8% in June, while […]
Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis Cytek® Cloud digital ecosystem Cytek® Biosciences has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool, establishing the industry’s first end-to-end platform that integrates the entire flow cytometry workflow, from panel design to data analysis, into one system. FREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq:
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.